Reply to: "Neutrophil-Rich Infusion Site Reactions after Continuous Subcutaneous Application of Foslevodopa/Foscarbidopa".
作者信息
Yoshihara Nagisa, Watanabe Rei, Nishikawa Noriko, Hattori Nobutaka
机构信息
Department of Dermatology and Allergology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Department of Neurology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
出版信息
Mov Disord. 2025 Feb;40(2):391-392. doi: 10.1002/mds.30120. Epub 2025 Jan 11.
Abstract
摘要
相似文献
1
Reply to: "Neutrophil-Rich Infusion Site Reactions after Continuous Subcutaneous Application of Foslevodopa/Foscarbidopa".回复：“持续皮下应用福司来沃多巴/福司卡比多巴后富含中性粒细胞的输注部位反应”
Mov Disord. 2025 Feb;40(2):391-392. doi: 10.1002/mds.30120. Epub 2025 Jan 11.
2
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.晚期帕金森病患者连续皮下注射左多巴-卡比多巴的安全性和有效性：一项随机、双盲、阳性对照、3 期临床试验。
Lancet Neurol. 2022 Dec;21(12):1099-1109. doi: 10.1016/S1474-4422(22)00400-8.
3
Foslevodopa/Foscarbidopa: A Review in Advanced Parkinson's Disease.左旋多巴/卡比多巴肠凝胶：晚期帕金森病的综述
CNS Drugs. 2025 Jun;39(6):621-632. doi: 10.1007/s40263-025-01179-3. Epub 2025 Apr 8.
4
Neutrophil-Rich Infusion Site Reactions After Continuous Subcutaneous Application of Foslevodopa/Foscarbidopa.持续皮下应用左旋多巴/卡比多巴后富含中性粒细胞的输注部位反应
Mov Disord. 2025 Feb;40(2):389-390. doi: 10.1002/mds.30121. Epub 2025 Jan 11.
5
Foslevodopa/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion.福司列弗多巴/福卡比多巴经皮下输注后具有良好的耐受性，并能维持稳定的左旋多巴和卡比多巴暴露量。
J Parkinsons Dis. 2021;11(4):1695-1702. doi: 10.3233/JPD-212813.
6
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.帕金森病患者皮下持续输注左旋多巴/卡比多巴：一项为期12个月的单臂、开放标签3期研究的安全性和有效性结果
Neurol Ther. 2023 Dec;12(6):1937-1958. doi: 10.1007/s40120-023-00533-1. Epub 2023 Aug 26.
7
Metabolite profiling of foslevodopa/foscarbidopa in plasma of healthy human participants by LC-HRMS indicates no major differences compared to administration of levodopa/carbidopa intestinal gel.采用 LC-HRMS 对健康人体参与者血浆中的 foslevodopa/foscarbidopa 进行代谢物分析，结果表明与给予左旋多巴/卡比多巴肠凝胶相比无明显差异。
Pharmacol Res Perspect. 2024 Apr;12(2):e1190. doi: 10.1002/prp2.1190.
8
Comparability of Foslevodopa/Foscarbidopa Pharmacokinetics in Healthy Asian and White Participants.福沙左旋多巴/福沙卡比多巴在健康亚洲和白人受试者中药代动力学的可比性
Clin Pharmacol Drug Dev. 2023 Apr;12(4):407-415. doi: 10.1002/cpdd.1201. Epub 2022 Nov 16.
9
Continuous Subcutaneous Foslevodopa-Foscarbidopa in Parkinson's Disease: A Mini-Review of Current Scope and Future Outlook.帕金森病中持续皮下注射左多巴-卡比多巴：当前范围和未来展望的小型综述。
Mov Disord Clin Pract. 2024 Oct;11(10):1188-1194. doi: 10.1002/mdc3.14161. Epub 2024 Jul 11.
10
Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease.福司列弗多巴/福卡多巴：帕金森病的一种新皮下治疗方法。
Ann Neurol. 2021 Jul;90(1):52-61. doi: 10.1002/ana.26073. Epub 2021 May 4.
本文引用的文献
1
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.帕金森病患者皮下持续输注左旋多巴/卡比多巴：一项为期12个月的单臂、开放标签3期研究的安全性和有效性结果
Neurol Ther. 2023 Dec;12(6):1937-1958. doi: 10.1007/s40120-023-00533-1. Epub 2023 Aug 26.
2
Factitial panniculitis.人工性脂膜炎
Dermatol Clin. 2008 Oct;26(4):519-27, viii. doi: 10.1016/j.det.2008.05.013.
Zotero 插件